2980元處方藥的“神話”:國內網售輝瑞新冠口服藥再遭“閃退”( 四 )


參考資料:
1.ArbelR,WolffSagyY,HoshenM.NirmatrelvirUseandSevereCovid-19OutcomesduringtheOmicronSurge.NEnglJMed.2022Aug24.doi:10.1056/NEJMoa2204919.Epubaheadofprint.PMID:36001529.
2.WangY,ChenX,XiaoW,ZhaoD,FengL.RapidCOVID-19reboundinasevereCOVID-19patientduring20-daycourseofPaxlovid.JInfect.2022Nov;85(5):e134-e136.doi:10.1016/j.jinf.2022.08.012.Epub2022Aug19.PMID:35995309;PMCID:PMC9389848.
3.https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-top-line-results-phase-23-epic-pep-study
4.https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results
5.https://www.thepaper.cn/newsDetail_forward_20825048
6.https://emergency.cdc.gov/han/2022/han00467.asp